Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC)

February 20, 2026 updated by: LIN YANG, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Efficacy and Survival Prognosis Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

This study is a single-center, retrospective cohort study. The purpose is to evaluate different perioperative treatment options on the efficacy and survival prognosis of locally advanced GC/GEJC, clarify whether the tumor regression grade can influence survival of patients using neoadjuvant therapy. Moreover, we aim to explore the clinical and pathological characteristics that will affect the long-term survival benefit of patients who underwent perioperative treatment.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100021
        • Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients who had locally advanced GC/GEJC

Description

Inclusion Criteria:

  • (1) Pathologically diagnosed as gastric adenocarcinoma or esophageal-gastric junction adenocarcinoma, and has not received any anti-tumor treatment before (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.)
  • (2) cT3-4N+M0 (according to AJCC version 8 stage) confirmed as resectable by CT or MRI.
  • (3) Patients who underwent adjuvant therapy before surgery.
  • (4) After neoadjuvant therapy , radical resection was performed at the Cancer Hospital of the Chinese Academy of Medical Sciences.
  • (5) Patients who have complete clinical, pathological and imaging data.

Exclusion Criteria:

  • (1) It is known that peritoneal metastasis or peritoneal irrigation solution cytology is positive (CY1P0) or there is distant metastasis (according to the 8th edition of AJCC).
  • (2) There are unresectable factors, including irresectable tumor causes or surgical contraindications that are irresectable or refuse surgery.
  • (3) Those who have suffered from other malignant tumors within 5 years or at the same time, except for cured skin basal cell carcinoma and cervical cancer in situ and breast cancer in situ.
  • (4) Those who have had radiotherapy, interventional treatment and other local therapists before surgery.
  • (5) Patients whose key diagnosis and treatment information records were missing.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
chemotherapy
patients who only used chemotherapy during neoadjuvant treatment
Procedure: Chemo only
Patients who only used chemotherapy during neodajuvant treatment period
Other Names:
  • chemothreapy
immunochemotherapy
patients who used immunotherapy combined with chemotherapy during neoadjuvant treatment
Procedure: Immunochemotherapy
Patients who used immunotherapy combined with chemotherapy during neodajuvant treatment period
Other Names:
  • immunotherapy combined with chemotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
OS
Time Frame: From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented death from any cause, assessed up to 100 months.
overall survival
From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented death from any cause, assessed up to 100 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
EFS
Time Frame: From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 100 months.
event free survival
From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 100 months.
DFS
Time Frame: From the start date of cycle 1 (each cycle is 14 days or 21 days) adjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.
disease free survival
From the start date of cycle 1 (each cycle is 14 days or 21 days) adjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2026

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

January 28, 2026

First Submitted That Met QC Criteria

February 20, 2026

First Posted (Actual)

February 24, 2026

Study Record Updates

Last Update Posted (Actual)

February 24, 2026

Last Update Submitted That Met QC Criteria

February 20, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NCC5964

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Clinical Trials on Chemo only

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe